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Abstract: In the last several years, researchers have exhibited an intense interest in the 
evolutionarily conserved signaling pathways that have crucial roles during embryonic 
development. Interestingly, the malfunctioning of these signaling pathways leads to several 
human diseases, including cancer. The chemical and biophysical events that occur during 
cellular signaling, as well as the number of interactions within a signaling pathway, make 
these systems complex to study. In silico resources are tools used to aid the understanding 
of cellular signaling pathways. Systems approaches have provided a deeper knowledge of 
diverse biochemical processes, including individual metabolic pathways, signaling networks 
and genome-scale metabolic networks. In the future, these tools will be enormously 
valuable, if they continue to be developed in parallel with growing biological knowledge. 
In this study, an overview of the bioinformatics resources that are currently available for 
the analysis of biological networks is provided. 
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1. Introduction  
The term ―systems biology‖ has emerged recently to describe the frontier of cross-disciplinary 
research in biology. The suffix ―Omics‖ encompasses a variety of new technologies that can help 
explain both normal and abnormal cell pathways, networks, and processes via the simultaneous 
monitoring of thousands of molecular components. Omics studies encompass many technologies, 
including genomics (the quantitative study of protein-coding genes, regulatory elements and 
noncoding sequences), transcriptomics (the quantitative study of RNA and gene expression) [1], 
proteomics (the quantitative study of protein abundance and protein modifications) [2], and 
metabolomics (the quantitative study of metabolites and metabolic networks) [3]. Omics studies also 
include research areas that have developed in the era of post-genomic biology and medicine, such as 
pharmacogenomics (the quantitative study of how genetics affects a host’s response to drugs) and 
physiomics (the quantitative study of physiological dynamics and the functions of whole organisms), 
as well as other fields, including nutrigenomics (a rapidly growing discipline that focuses on 
identifying the genetic factors that influence the body’s response to diet and how the bioactive 
constituents of food affect gene expression), phylogenomics (the analysis of genome data and 
evolutionary reconstructions, especially phylogenetics) and interactomics (the study of molecular 
interaction networks). The systems biology field overlaps with several emerging, post-genomic 
disciplines, such as synthetic biology [4], systems microbiology [5], systems biotechnology [6], 
integrative biology [7], systems biomedicine [8], and metagenomics [5]. Numerous definitions of 
systems biology have been proposed [9], but to date, no universally accepted definition has been 
accepted, which reflects the difficulty of encompassing a heterogeneous school of thought with a 
comprehensive yet concise definition. However, each of the proposed definitions revolves around a 
fundamental understanding of biological systems that is based on the underlying interactions of  
the components. 
Recent experimental and theoretical work has begun to supply lacking biological details. In a small 
but growing number of systems [10,11], the examination of signaling events at the level of individual 
molecular interactions is possible. The theoretical and computational counterparts to these experimental 
findings are also now emerging [12]. These tools enable researchers to apply basic chemical principles 
to predict and analyze the functioning of molecular circuits at the single-molecule level. 
The evasiveness of the gene concept has become fully apparent only in the last decade [13] with the 
analysis of sequenced genomes and extensive studies of the transcriptome with new techniques. 
Several facts highlight the complexity of the relationship between an organism’s phenotype and its 
genome [14]. As a result, in the past five years, the concept of the gene has been the subject of 
substantial revisions [13,15]. 
Enormous progress has been made in understanding critical cellular processes, such as cell cycle 
regulation, DNA repair, apoptosis, transcription, cell migration, and matrix structure, which are 
essential to the understanding and treatment of cancer [16–20]. However, cancer is not only a disease 
of cells but is also a disease of various systems and components that interact at both a molecular and 
cellular level to lead to the initiation and progression of the disease [21–24]. These interacting systems 
are intertwined by crosstalk between the genes in a cancer cell, the signal transduction pathways within 
a cancer cell, the cells in a tumor, the tumor and the microenvironment, and the individual and the 
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macro-environment. Furthermore, the changing interactions of these systems in a dynamic 
environment underscore the inherent complexity of the disease. Until recently, a reductionist approach 
to cancer research has been made in order to understand each of these components. However, further 
integration across components or scales has been limited, primarily by a lack of the technology and 
tools needed to interrogate these systems at a higher level. 
In the past 10 years, new technologies have been developed that have generated extensive genomic 
and proteomic data, as well as other types of genome-wide information [25,26]. Additional novel 
technologies have also made the imaging, isolation of rare cells, and organotypic culturing procedures 
possible. Together, these developments have facilitated an expansion of cancer research to include an 
integrative systems approach [27]. 
This review considers the chemical and physical types of complexity within cancer signaling 
pathways. Furthermore, the tools available to analyze signaling network data, which are accessible to 
specialized bioinformaticians and general research scientists, are detailed. 
2. The Biochemical Networks in Cancer 
The full complexity and the multidimensional nature of biochemical networks that take into account 
the genome, transcriptome, proteome, and metabolome data highlight the intricacy and 
interdependency of these systems (Figure 1). Understanding how biological networks behave could 
help to explain the general mechanisms of tumor cell systems. 
Figure 1. Biological networks represent various types of molecular interactions, including 
(1) enzyme catalysis, (2) the post-transcriptional control of gene expression by proteins,  
(3) the effect of metabolites on gene transcription mediated by a protein, (4) protein 
interactions, (5) the effect of a downstream metabolite on transcription, (6) feedback 
inhibition/activation of an enzyme by a downstream metabolite, and (7) the exchange of a 
metabolite outside of the system. The solid lines represent direct interactions, and the 
discontinuous lines represent possible interactions in tumor cells. 
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The types of networks that are currently available include, but are not limited to, protein interaction 
networks, genetic interaction networks, transcription factor-target regulation networks, miRNA-target 
regulation networks, kinase-substrate phosphorylation networks, and metabolic pathway networks. 
Analogous to a sequence analysis, the development of a biological network has three similar  
stages: (1) the construction of the network by large-scale experimentation and computational 
predictions [28–30], (2) a pairwise network comparison to find the conserved edges as ―interologs‖ or 
―regulogs‖ [31] with the building of general network alignment tools [31,32], and (3) an investigation 
of the conservation level and the evolutionary changes of the biological network.  
Biological networks are characterized by their functional relationships, such as the binding, 
expression, regulation, and phosphorylation of proteins. Biological networks could be categorized as 
collaborative or regulatory networks. Collaborative networks are the biological networks with 
reversible edges (i.e., either the edges are undirected or directed but reversible). In this study, the term 
reversibility means that a reversed edge is biologically possible between a pair of nodes. Regulatory 
networks have irreversible edges (i.e., a reversed edge may not be biologically possible). By this 
definition, transcription factor-target regulation networks, miRNA-target regulation networks, and 
kinase-substrate phosphorylation networks fall into the regulatory network group and protein 
interaction networks, genetic interaction networks, and metabolic networks fall into the collaborative 
network group [33].  
The transcriptional regulation of gene expression is carried out by transcription factors that bind to 
the transcription start site upstream of a gene. The recognition of a binding site is often specific to the 
DNA sequence [34]. The post-translational modification of a kinase’s substrate also involves the 
recognition of sequence patterns in the substrate’s phosphorylation site [35]. A protein’s function 
gradually changes as the protein’s sequence changes; however, most proteins do not change functions 
radically as their sequences are conserved. Metabolic enzyme networks are constructed using enzymes 
as nodes. The edges between two nodes are connected if the product of one node serves as the 
substrate of the other node. Metabolic reactions process chemical compounds into energy and 
nutrition, and most are essential for cellular survival. 
Therefore, the ultimate goal of cancer systems biology research is to understand how individual 
molecule changes affect the function, organization and collaboration of cells. Certain factors may also 
influence and shape the landscape of tumor biological networks. The external environment has been 
shown to influence the conservation of regulatory relationships and network motifs in prokaryotic 
transcription factor-target networks [36]. Relationships tend to be conserved in organisms that live in 
similar environmental niches, despite large evolutionary distances. Whole-genome duplication events 
rapidly reorganize transcription regulation networks through the survival and functional divergence of 
the organisms with genome duplications [33]. In addition, the regulatory networks could affect the 
survival of organisms with duplicated genes by feedback mechanisms [37].  
Genomic, proteomic, and metabolomic technologies have given researchers the tools to unravel 
additional underlying mechanisms that lead to cancer, which has resulted in an explosion of data. 
However, to yield significant insight, the systematic integration of data for cancer research requires a 
systems biology computational approach. This approach must combine the use of existing knowledge 
to account for what is known with the massive amounts of high-throughput data to determine what is 
not known. Biological knowledge is accounted for, using pathway models and mechanistic dynamic 
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simulations of biological constituents (e.g., genes, proteins, and metabolites organized in pathways and 
networks). Unknown relationships are accounted for by data mining or reverse-engineering approaches 
that extract patterns and relationships from high-throughput data. Both of these approaches rely on the 
development of experimental methods that analyze the interaction, expression, and localization of 
biological molecules in a quantitative manner. 
3. Bioinformatic Tools for Pathway Analysis 
Along with the ability to generate a large amount of data per experiment, high-throughput 
technologies have also brought experimental challenges, such as translating large amounts of data into 
a better understanding of biological phenomena. Independent of the platform and the analysis methods 
used, in many cases, the results of a high-throughput experiment are lists of differentially expressed 
genes. Translating these lists into a better understanding of underlying biological phenomena is a 
common challenge faced by all researchers. In particular, placing high-throughput data into context 
within a whole organism remains a daunting challenge.  
Currently, the overrepresentation approach [38] and the functional class scoring techniques [39], 
which are used to analyze high-throughput data, are limited by the fact that each functional category is 
analyzed independently without a unifying analysis at a pathway or system level. This approach is not 
well-suited for a systems biology approach that aims to account for system-level dependencies and 
interactions, as well as to identify perturbations and modifications at a pathway or organism  
level [40]. Several pathway databases, such as KEGG [41], BioCarta, and Reactome [42], currently 
describe metabolic pathways and gene signaling networks, thereby allowing a more complex and 
useful analysis in a pathological and non-pathological manner. All of the pathway analysis tools 
currently available use the overrepresentation approaches and fail to take advantage of the much richer 
data contained in these resources. GenMAPP/MAPPfinder [43,44] and Gene-Sifter use a standardized 
Z-score. PathwayProcessor [45], PathMAPA [46], Cytoscape [47], and PathwayMine [48] use Fisher’s 
exact test. MetaCore uses a hypergeometric model, while ArrayXPath [49] offers both Fisher’s exact 
test and a false discovery rate. VitaPad [50] and Pathway Studio [51] focus on visualization 
approaches alone and do not offer any detailed analyses. Finally, the impact analysis method, which is 
implemented as a Web-based tool, and Pathway-Express, which is freely available as part of the Onto-
Tools software, use a systems biology approach to identify pathways that are significantly impacted by 
any condition that has been monitored by a high-throughput gene-expression analysis. The impact 
analysis method incorporates a classical probabilistic component along with important biological 
factors that are not captured by existing techniques, including the magnitude of the expression change 
of each gene, the position of the differentially expressed genes on the given pathways, the topology of 
the pathway that describes how these genes interact, and the type of signaling interactions between them. 
Pathway-level analysis is a powerful approach that enables the interpretation of post-genomic data 
at a higher level than the individual biomolecules (Figure 2). The evidence of pathway dysregulation is 
combined, which allows for the identification of additional pathways with altered activities that would 
not be highlighted when the analysis is applied to any of the functional levels alone (i.e., the genome, 
transcriptome, proteome or metabolome). 
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Figure 2. A map of the VEGF signaling pathway (as an example of an important target in 
cancer therapy) obtained from KEGG is shown [41]. The gene expression studies are used 
as an independent predictive method for the prognosis. In cancer genomics studies, 
tremendous effort has been devoted to pathway-based analysis. Pathway analysis is a 
promising tool to identify the mechanisms that underlie disease, the adaptive physiological 
compensatory responses and new avenues for investigation. Different pathways have 
different biological functions. Thus, studying each pathway separately is reasonable. 
Among the many pathways, only a few have been shown to have predictive power for the 
development of cancer. In this sense, KEGG could be a useful tool to identify genetic 
signatures [52]. 
 
4. Bioinformatics Tools for Systems Biology 
The field of bioinformatics has blossomed in the last 10 years, and as a result, a large, increasing 
number of researchers are generating computational tools to solve problems relevant to biology. While 
many systems biology approaches involve mathematical and computational modeling, the development, 
maintenance, and dissemination of tools for systems biology are significant challenges. Examples of 
these challenges include the development of data repositories, data standards and software tools for the 
simulation, analysis and visualization of system components, such as biochemical networks (Figure 3). 
Another difficulty is the application of high-throughput molecular profiling technologies, which often 
require sophisticated data processing and analyses. These analyses also typically involve elements of 
signal processing and statistical analysis. As the resulting quantitative measurements are transferred to 
Int. J. Mol. Sci. 2012, 13 6567 
 
 
formal mathematical models for simulation purposes, the endeavor becomes more like systems biology 
and less like bioinformatics. 
The practice of systems biology seeks to comprehend the complexity of organisms or organism 
subsystems by combining many different kinds of data, such as mRNA levels, protein levels,  
protein-protein interactions, protein-DNA interactions, protein modifications, and biochemistry data, to 
create predictive models [53]. The computational analysis of this data has become increasingly 
important, and many more tools and models for the interpretation of healthy and non-healthy 
biological data have been developed in recent years. However, not all of these methods are publicly 
available or permit bulk online submissions. Moreover, some tools, particularly the tools for individual 
organisms, require special training, and these tools may also be mutually interdependent.  
Figure 3. An illustration of the multi-scale visualization of biological interactions using 
VisANT’s metagraph capability. VisANT [54] is an integrative software platform for the 
visualization, mining, analysis and modeling of biological networks. This software extends 
the applications of GO for network visualization, analysis and inference. The image shows 
the biological networks between the molecules that belong to the VEGF signaling pathway. 
(1) VEGF, (2) VEGFR2, (3) COX2 and (4) p33. 
 
As biological research accelerates through the development of new technologies and instrumentation, 
biological databases have become an indispensable part of scientific research. The construction and 
maintenance of primary databases, such as GenBank [55] and Protein Data Bank [56], have long been 
recognized as important bioinformatics work. Primary biological databases serve as repositories for 
experimentally derived information and are also the basis for the development of secondary databases 
that capture higher-level knowledge. An example of a secondary database is the Pfam database of 
proteins families and domains [57]. Concomitantly with the development of biochemical systems 
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biology, the databases that capture the properties and processes of biochemical networks have emerged 
as an important niche of secondary biological databases. The ecosystem of these databases and the 
tools associated with these databases are rapidly growing and include metabolic pathway databases 
organized around the BioCyc project [58], a database of the human biological pathways [42], a database 
of the interactions between small molecules and proteins [59], and databases of protein-protein 
interactions [60]. As these databases attempt to reconstruct and organize information concerning the 
interactions between cellular components, they also attempt to build higher-level knowledge and 
theories concerning the biological processes they archive. This in silico knowledge is greatly needed 
because the integral complexity of most biological processes is beyond what is comprehensible to the 
human mind. Therefore, these ―systems biology databases‖ often provide important foundations for the 
quantitative modeling of biological systems. In certain cases, these databases allow for the direct 
export of mathematical models. Additionally, the first collections of the mathematical models of 
biological processes have been developed (databases of models), which solely archive and curate the 
mathematical models in the Systems Biology Markup Language (SBML) for future use and  
refinement [61]. Tools for the visualization of network structures and the overlay of simulated and 
experimental data are greatly needed for systems biology research. These tools include the yEd graph 
editor for editing networks and tools for the visualization of ―omics‖ data in the context of biochemical 
networks, such as Cytoscape [47] (Figure 4) and the Pathway Tools Omics Viewer [62]. 
The rationale for establishing a Working Group on Agents in Bioinformatics (BIOAGENTS) was to 
improve the field of bioinformatics by designing and implementing new, flexible information and 
communication technology tools. These tools should be able to support the analysis of biological data, 
partially distribute the computation burden of the large amounts of high-throughput data, and reduce 
the need to transfer large amounts of data. From this perspective, software agents can play a major role. 
The scope of the Working Group was to promote collaborations between software agents and the 
bioinformatics communities with the aim of creating synergies for the modeling of complex  
biological systems [63]. 
The combination of software agents with bioinformatics presents a two-fold opportunity. First, the 
domain of bioinformatics, which contains extensive and growing database resources and analysis tools, 
provides an appropriate domain for the application of agent technologies. Second, the combination of 
agents with bioinformatics allows for the deployment and testing of agent systems in a real-world 
setting with the possibility of making substantial contributions to human society. Additionally, a 
distinct and identified need exists for good solutions to improve the performance of existing 
bioinformatics systems, and agents may be able to contribute to this needed improvement. In this sense, 
there is a notably strong synergy between the two domains. This picture is both enhanced and 
complicated by the introduction of relevant infrastructure technologies that facilitate both bioinformatics 
and agent-based computing. For example, the Grid has become increasingly important to both 
communities and suggests a convergence to a service-oriented vision of bioinformatics underpinned by 
Grid-based virtual organizations. However, significant challenges still exist. Researchers from both 
communities generally require education in the other domain, and work must be undertaken to ensure 
that any solutions developed across both areas satisfy the needs of both domains. In many cases, the 
language of discourse is so distinct that the discussion of key issues becomes problematic. Additionally, 
the introduction of new technologies, such as the Grid, requires further efforts to understand and adopt 
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the new technology, as well as improve the immaturity of fully deployed systems. Thus, the maturity at 
the interface is a key challenge. 
Figure 4. Cytoscape is an open-source bioinformatics software platform for visualizing 
molecular interaction networks and integrating these networks with other state data. 
Cytoscape was used to model the interaction networks for VEGF-A (also called vascular 
permeability factor (VPF). The software found 56 interaction networks at a pathway level, 
and one of these interaction networks, the HIF-2-α network, is shown with 40 nodes and 
114 edges. The importance of this figure is to provide the reader understanding of the level 
of complexity to which we refer when we speak of interactions at the gene or protein level 
illustrating this by VEGF-A pathway. Each node represents a molecule that interacts with 
HIF-2-α; in this case 40 molecules interact with this important marker in different 
malignancies, through 114 edges. 
 
5. The Virtual Cell 
Computational systems biology is a rather new science [64]; however, its roots can be found in 
theoretical and mathematical biology. An example of these origins can be observed in the field of  
cell-cycle modeling. In the 1960s, mathematical models were proposed that attempted to explain key 
aspects of cell-cycle regulation from phenomenological observations. The field began to explode in the 
early 1990s when data were published on the underlying molecular regulatory network [65].  
The cell cycle refers to a sequence of events that leads to the correct duplication of cells [66].  
A complex regulatory network controls the proper order of the events within the cell cycle. The core 
controllers of this network in all eukaryotes are complexes of the Cdk and cyclin molecules. Various 
Cdk/cyclin pairs regulate the critical transitions of the cell cycle. These pairs initiate DNA replication 
at the transition from G1 to S-phase, and they play key roles in the induction of mitosis. In addition, 
Cdk/cyclin pairs inhibit the last steps of the cell cycle, which include the separation of the 
chromosomes at the end of mitosis and cell division. Key cell-cycle transitions are regulated by 
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checkpoints, which ensure that cells start DNA synthesis only if adequate amounts of nutrients and 
growth factors are present, prevent mitosis from occurring until DNA replication is properly finished, 
and keep the chromosomes from separating unless the mitotic spindles are intact. If a problem arises in 
the cell cycle, the checkpoints signal to the core Cdk/cyclin modules to inhibit the further steps of  
the cell cycle [67]. 
Single-cell measurements and other new technologies have enabled the development of detailed, 
quantitative models of cell-cycle regulation. Mass spectrometry has provided data on protein level 
fluctuations during the cell cycle, identified members of important protein complexes, and revealed the 
phosphorylation states of the Cdk-regulated proteins [68]. Future targeted analyses of the key cell-cycle 
components will provide valuable data for biological modeling of the tumor cell cycle. 
Several modeling platforms have been used in cell-cycle research [69]. These platforms usually 
guide the user through the process of model building to some type of data analysis. JigCell has been 
developed precisely for cell-cycle model simulations and data fitting [70]. This program can run 
multiple parameter sets to simulate various mutants, and it includes a comparator that tests how well 
the simulations fit the physiological details of the mutants. Although defining a suitable objective 
function for data that is not time dependent is difficult, JigCell provides tools for these estimations. 
Indeed, parameter optimization is one of the major challenges for modeling. High-throughput 
measurements rarely give reliable kinetic rates, and most often, these rates should be estimated from 
concentration profiles using a parameter optimization algorithm [71–73]. 
Searching for missing values is an example of the types of jobs that computational tools can 
undertake; missing values frequently pose problems in gene expression microarray experiments as they 
can hinder downstream analysis of the datasets. Although gene expression microarrays have developed 
much during the past years, the technology is still rather error prone, resulting in datasets with 
compromised accuracy and coverage. In particular, the existence of missing values due to various 
experimental factors still remains a frequent problem, especially in cDNA microarray experiments. 
Experimental data can also be used to infer undiscovered molecular interactions and propose the 
existence of protein regulation. Specific useful tools can handle this type of network data [74], and 
methods have been developed to search for missing interactions and infer network topology [75]. 
Because high-throughput data are available for the cell cycle of various organisms, researchers can 
start to think about how to fuse this high-throughput data to measurements on single gene perturbations 
to achieve a detailed understanding of the system. The computational identification of cell-cycle 
related transcription factors [76,77] is a promising initial result for these studies. 
Another layer of complexity in cell-cycle models is the spatial distribution of regulatory molecules. 
Many crucial events happen in the nucleus, and many molecules are moved in or out of the nucleus 
during the cell cycle. Despite these localization limits, only a few cell-cycle models have considered 
the compartmentalization of the cell [78]. 
Recently, biological modeling has been enriched by new concepts that have helped to delineate  
cell-cycle models into sub-networks [79], find the exact timing of the cell-cycle transitions [80] and 
determine the irreversibility of these transitions. 
Placing the core cell-cycle machinery into the larger context of cell physiology, deciphering how a 
cell copes with checkpoint problems, determining how a cell responds to environmental changes, and 
understanding why some cells leave the cell cycle to commit suicide remain major challenges for 
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future work. Understanding these issues will lead us to the future goal of understanding how 
perturbations of the human cell cycle machinery lead to tumor formation. Indeed, the mathematical 
modeling of cancer development is another active research field [81–83]. Various ideas exist on how 
to model tissue growth computationally [84,85]. Predictive cell-cycle models embedded into complex 
tissue models can help us understand the dynamics of cancer formation (Figures 5 and 6). 
Figure 5. The cancer pathways obtained from KEGG are shown [41]. The complexity of 
the carcinogenic mechanisms leads to heterogeneity in the molecular phenotypes, 
pathology, and prognosis of cancers. Systems biology approaches leverage the signature 
genes as a representation of the changes in the signaling pathways, instead of interpreting 
the relevance between each gene and the resulting phenotype. At the bottom right side of 
the figure is represented the complex system of communication that exists in the signaling 
pathways in cancer (KEGG map05200). Within this complex of roads we can find among 
others, the signaling pathways that characterize kidney cancer (KEGG map05211). 
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Figure 6. The challenge of understanding intracellular activity is being addressed by 
computational approaches, such as the Virtual Cell System. While this graphical 
representation of the VEGF network provides additional information not available by 
considering the individual pathways separately, it is still a vast simplification. The graphic 
is merely a static representation of several dynamic processes occurring concurrently with 
several intertwined feedback loops. The only way to effectively study the effect of either 
mutations or therapeutic interventions is to create a quantitative model of the network that 
integrates the dynamics of the individual pathways and their interconnections, which can 
be simulated on a computer. By representing aspects of an in silico cell, the model can then 
be used to explore a variety of questions. 
 
The Virtual Cell [86] is a unique computational environment for the modeling and simulation of 
cell biology. This platform has been specifically designed to be used by a wide range of scientists from 
experimental cell biologists to theoretical biophysicists. The creation of biological or mathematical 
models can range from simple models used to evaluate hypotheses or interpret experimental data to 
complex multilayered models used to probe the predicted behavior of complex, highly nonlinear 
systems. These models can be based on both experimental data and purely theoretical assumptions. 
The Virtual Cell has been deployed as a distributed application that is used over the internet. Users 
can build complex models with a web-based Java interface to specify compartmental topology, 
compartmental geometry, molecular characteristics, and relevant interaction parameters. The Virtual 
Cell automatically converts biological descriptions into a corresponding mathematical system of 
ordinary and/or partial differential equations. Distinct biological and mathematical frameworks are 
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encompassed within a single graphical interface. A user, competent in mathematics, may directly 
specify the complete mathematical description of the model by bypassing the schematic interface. The 
Virtual Cell will then solve the equations by applying numerical solvers and generate appropriate 
software code to perform and analyze simulations. The results can be displayed and analyzed online or 
downloaded to the user’s computer in a variety of formats. The software is freely accessible to all 
members of the scientific community. 
6. Systems Biology and Cancer 
To understand how a cancer cell is functionally different from a normal cell, it is necessary to assess 
the changes in the dynamics of overall networks, rather than the changes in the individual pathways. 
As networks tend to be complex with extensive crosstalk between pathways and important feedback 
loops, representing networks in the form of a computational model that can be used for a rigorous 
analysis is crucial. As with most complex diseases, in the instance of cancer, an additional 
complication arises in that for many aspects of the diseases, several different scales must be integrated. 
Recognizing dynamic signatures can help improve the diagnosis of cancer, and an understanding of the 
mechanisms that lead to cancer can help with the design of sophisticated perturbations that can disrupt 
cancer progression. 
Despite significant advances in the understanding of tumor biology, improvements in patient 
outcomes in terms of cure rates and survival times have not met many expectations. In the past  
50 years, major advances have been made in scientific knowledge and technology. Additionally, 
increasing amounts of money are being spent to meet the clinical challenges of cancer. However, 
further progress is certainly needed. 
Systems biology has emerged during the past decade as a powerful new paradigm for life-science 
research. This discipline is based on the premise that the properties of complex systems, which consist 
of many components that interact with each other in nonlinear, non-additive ways, cannot be 
understood solely by focusing on the components. The system as a whole has emergent properties that 
are not visible at the level of the individual parts. The availability of high-throughput data generation 
technologies, such as DNA microarrays, has made it possible to apply this paradigm in molecular 
biology and biomedicine. Large-scale transcriptional data allows the focus to shift from individual 
genes in linear pathways to large-scale networks of interacting genes. In many cases, the properties of 
the aggregate network, which possibly interact with the extracellular environment, are at the heart of 
pathological changes, such as cancer. Moreover, the system properties of interest are often embodied 
in its dynamics. For instance, changes in the structure of the network through mutations or epigenetic 
effects can lead to changes in the network dynamics that result in different physiological properties. In 
many cases, especially in the case of cancer, the phenomena at different scales are connected, such as 
the molecular- and tissue-level scales in tumor growth. The use of mathematical models is the natural 
framework for the study of the structure and dynamics of networks, which is perhaps the defining 
characteristic of the systems biology paradigm [87]. 
A key feature of cancer development is encapsulated in the interactions between the intracellular 
networks and the extracellular environment. Ultimately, a comprehensive understanding of cancer 
must link events at the molecular level with events at the tissue-level, organism level, and 
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environmental level. These relationships can only be found with multi-scale mathematical models that 
integrate quantitative information at different scales, which is precisely the approach of systems biology. 
To make progress in oncology research, more investigators and grant money have been added; 
however, these investments may not lead to more effective therapies. Further progress may require an 
entirely new approach, such as computational oncology. In the past, oncologists and oncology 
investigators viewed themselves as entirely separate from mathematicians and physicists. Bringing 
these once-disparate groups together to work on a common problem is long overdue and has spurred 
the development of the field of computational oncology. 
The study of systems biology requires the modeling of vastly complex components, which interact 
with each other on many levels. These models are crucial to the understanding of complex biological 
systems and are referred to as in silico models [88]. The dysfunction of any component of the network 
can lead to diseases, such as cancer, and the use of computational oncology techniques has allowed the 
development of sophisticated models to deepen our understanding of the origins of malignancies (Figure 7). 
Using mathematical models to understand the behavior of cancer has generally proceeded in two 
directions: descriptive models and mechanistic models [89]. Descriptive models examine the gross 
characteristics of a tumor, such as its size, growth pattern and overall dynamics, and these models may 
seem the most intuitive to clinical oncologists. Mechanistic models focus on the various processes that 
lead to tumor growth in an attempt to understand the relative contributions of various components to 
overall tumor behavior. Both of these approaches are important for the further understanding of tumor 
biology. With data from in vitro experiments and animal models to develop and improve the 
mathematical models, the accuracy of the resulting models has been greatly improved. 
Although current medicine employs single genes as molecular markers, thousands of markers 
analyzed simultaneously will probably be used as molecular marker profiles in the future. These 
molecular-oriented diagnostic techniques will be linked to the prediction and prevention of disease on 
a molecular level [29]. These developments are directly dependent on the future of computational 
oncology, which needs to combine large-scale and genome-wide data with biostatistical and 
bioinformatics analyses of model systems. This complex analytical process is the basis of a new 
scientific paradigm known as ―integrative genomics‖. 
The use of systems biology for the study of cancer involves addressing the complex nature of the 
disease in the human body. Much experimental progress is being made to address these issues; 
however, the power of computation and computational modeling is still needed to help bridge this gap. 
The development of combined systems biology computational and experimental approaches to 
improve the understanding of human in vivo tumor behavior can greatly aid in improving 
pharmaceutical drug development and create a more rational, predictive approach to the application of 
therapeutic strategies. 
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Figure 7. The ability to extract meaningful data from ever-expanding databases is an 
important area of development in computational oncology. Specifically, the relationship 
between genes and cancer is being documented by data-mining from large databases.  
In this figure, the interaction network for the markers involved in neoplasms is shown. 
DisGeNET [90] is a plugin for Cytoscape to query and analyze a network representation of 
human gene-disease databases. This figure illustrates the importance of addressing 
problems, such as which are the genes annotated to prostate, sarcoma or retinoblastoma 
neoplasms, for example, in expert-curated databases. 
 
7. Conclusions 
High-throughput methodologies have allowed biological studies to move from a reductionist 
approach, such as the isolation of specific pathways and mechanisms, to a more integrative approach in 
which biological systems are seen as a network of interconnected components that provide specific 
outputs and functions in response to different stimuli. 
The integration of known cancer genes into protein and signaling networks reveals the 
characteristics of these cancer genes within the networks. This approach shows that cancer genes often 
function as network hub proteins, which are involved in many cellular processes and form focal nodes 
for the exchange of information between many signaling pathways. 
By providing a systematic and integrative framework for incorporating data and outputting 
predictions, systems biology has the potential to revolutionize the understanding of the mechanisms 
underlying cancer formation and to facilitate novel applications for cancer therapeutics. 
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